MADISON, Wis. & DELFT, Netherlands--(BUSINESS WIRE)--Jan. 22, Bruker AXS Inc., an operating company of Bruker BioSciences Corporation (NASDAQ: BRKR), and a leading global provider of advanced X-ray solutions for the life and advanced materials sciences, announced today that it has been selected to participate in the EUR 17.6 million (approximately US $ 22.2 million) Cyttron project in The Netherlands. The project is half funded by the Dutch government, and over three years Bruker AXS expects to receive EUR 750,000 in matching funds.

Participants in the Cyttron consortium are the University of Leiden, the Leiden University Medical Centre, the Technical University Delft, University of Utrecht, and the companies FEI (Eindhoven), Bruker Nonius (Delft, a Bruker AXS subsidiary) and KeyDP (Leiden), as specialists in electron microscopy, X-ray crystallography and drug design, respectively. A few international partners also will participate: the Imperial College London (UK), and the University of Antwerp (Belgium). The Cyttron project is headed by Prof Dr. J. P. Abrahams from Leiden University.

In order to enhance the knowledge infrastructure in The Netherlands, the Dutch government has decided to use a portion of its profits from natural gas exploration for the development of a "super microscope," called the Cyttron. Its goal is to zoom in on the molecular structure of a human cell. Although such an instrument does not yet exist, it is believed that it could be an important booster for medical research and drug design, or the development of production processes using micro-organisms.

For this Cyttron super microscope, molecular information and images acquired with X-ray crystallography, transmission electron microscopy, visible light microscopy, scanning microscopy and NMR will be integrated with advanced software. Moreover, these techniques will be modified for better compatibility with each other. This project will be executed by the Cyttron consortium.

Roger Durst, Ph.D., Chief Technology Officer and Vice President of R&D at Bruker AXS, commented: "We are excited to become a partner in this consortium which will not only accelerate the acquisition of knowledge of human cell structures but also enable the participants to develop new marketable technologies with the ultimate goal to improve structure based drug discovery."

Dr. Martin Haase, President and CEO of Bruker AXS and Senior Vice President of Bruker BioSciences, added: "Participation in the Cyttron consortium is an excellent step forward in Bruker BioSciences' strategy to become a broad provider of life science technologies. The X-ray crystallography R&D competency within Bruker AXS, and especially at Bruker Nonius in Delft, as well as the complementary nature of the technologies of our partners, gives us high confidence that the work of this consortium will lead to applicable results and marketable products within the drug discovery chain."

ABOUT BRUKER BIOSCIENCES

Bruker BioSciences, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. For more information about Bruker BioSciences Corporation, please visit www.bruker-biosciences.com.

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2002, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.